Hannah Slater

These study findings suggest that the response rate to immune checkpoint blockade may be dependent on the strength of immune selection occurring early in tumorigenesis.

The director of special projects at the Union for International Cancer Control spoke about the strategy released by the World Health Organization and what needs to occur to achieve the goals laid out by the organization.

The study evaluated the efficacy and safety of IV rigosertib in patients with high-risk MDS who had progressed on, failed to respond to, or relapsed after previous treatment with an HMA within 9 cycles over the course of 1 year after initiation of HMA treatment.

The study was evaluating spartalizumab in combination with dabrafenib and trametinib among untreated patients with stage IIIC or stage IV BRAFV600 mutation-positive cutaneous melanoma.

Researchers suggested that these findings support a change of the current screening guidelines for this specific risk group and support MRI screening.

Researchers indicated that “these results reinforce the idea that there can be biological differences in prostate cancers between different ancestral groups.”

Researchers indicated that these study findings could set a basis to pinpoint independent prognostic factors related to a treatment modality in patients with breast cancer and provide clarity for the assessment of surrogate markers for overall survival.

A survey of breast cancer survivors in the US showed that “patients were universally affected by COVID in terms of delays in breast cancer care.”

According to researchers, mindfulness-based intervention may have a positive effect on subjective measures of cognitive impairment in breast cancer survivors.

The FDA approved daratumumab in combination with carfilzomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 previous lines of therapy.

Researchers indicated that results of this study suggest the combination of dabrafenib and trametinib could serve as a much-needed treatment option for patients with BRAFV600E-mutated biliary tract cancer.

The FDA granted fast track designation to paxalisib for the treatment of patients with newly diagnosed glioblastoma with unmethylated O6-Methylguaninemethyltransferase promoter status who have completed initial radiation with concomitant temozolomide.

Results from a survey of psychosocial oncology professionals suggested that “there are significant ongoing concerns about funding and how services and research activity will be maintained in coming months and years.”

Early interim data from the registrational phase 2 TRIDENT-1 study of repotrectinib was reported by Turning Point Therapeutics, as well as regulatory feedback from the FDA regarding the TRIDENT-1 trial design.

The trial is evaluating pembrolizumab (Keytruda) in combination with cisplatin plus 5-fluorouracil for the first-line treatment of patients with locally advanced or metastatic esophageal cancer.

The findings supported the accelerated approval of rucaparib for the treatment of men with metastatic castration-resistant prostate cancer who have a deleterious BRCA mutation and who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

These findings suggest that the current lung cancer screening guidelines undercount African Americans and should therefore be modified to avoid worsening the observed disparities between white and African American ever-smokers in lung cancer outcomes.

The study is designed to evaluate the safety and tolerability, pharmacodynamics, and preliminary efficacy of ACE1702 in patients with advanced or metastatic HER2-expressing solid tumors.

The breast cancer expert discussed research recently published in Cancer Medicine, which suggested that delays in adjuvant chemotherapy are associated with worse survival in this patient population.

The multi-institution trial randomized patients with acute myeloid leukemia to receive either a combination of venetoclax and azacitidine or azacitidine plus placebo.

Researchers indicated that these findings suggest providers should avoid delays and begin chemotherapy no later than 90 days after surgery, regardless of the patient’s breast cancer subtype or age.

If approved, durvalumab could be administered intravenously every 4 weeks at a fixed dose of 1500 mg in unresectable stage III NSCLC after chemoradiation therapy and in previously treated advanced bladder cancer.

Researchers indicated that especially among women considered to be midlife, metastatic breast cancer creates a high economic burden through lost productivity.

The FDA granted priority review to the new drug application for trilaciclib for patients with small cell lung cancer being treated with chemotherapy.

This study found that implementation of the enhanced recovery after surgery pathway combined with prehabilitation programs can significantly change the postoperative course of patients.

Though the results still need to be confirmed, researchers suggested these findings indicate a need to better understand how BMI affects the biology, progression, and treatment efficacy of breast cancer.

The Oncologic Drugs Advisory Committee voted in favor of the available data supporting the efficacy of remestemcel-L in pediatric patients with steroid-refractory acute graft-versus-host disease.

The implementation of optimized workup as a diagnostic workup in patients with head and neck cancer led to a significant reduction in the time-to-treatment interval.

Researchers found that breast cancer survivors who were prescribed adjuvant endocrine therapy and regularly performed moderate physical activity reported better health-related quality-of-life.

Study findings suggested that survivors with severe hearing loss are at a significantly increased risk for neurocognitive deficits, independent of what type of therapy they receive.